Table 1.
Summary and characteristics of patients (patients, N = 35)
| Characteristic | |
|---|---|
| Age (years, median) (range) | 58 (34–80) |
| Gender | |
| Male | 16 (45.7%) |
| Female | 19 (54.3%) |
| BMI kg/m2 (mean) (range)b | 23.7 (17.0–33.7) |
| Cancer type | |
| Adenocarcinoma | 34 (97.1%) |
| Neuroendocrine carcinoma | 1 (2.9%) |
| Initial systemic chemotherapy | |
| FOLFIRI | 33 (94.2%) |
| FOLFOXIRI | 1 (2.9%) |
| Cisplatin + Etoposide | 1 (2.9%) |
| 1st line combined target therapy | |
| Bevacizumab | 27 (77.1%) |
| Cetuximab | 6 (16.1%) |
| Panitumumab | 1 (2.9%) |
| None | 1 (2.9%) |
| Colectomy | |
| Yes | 20 (57.1%) |
| No | 15 (42.9%) |
| Primary tumor location | |
| Right colon | 7 (20.0%) |
| Left colon | 28 (80.0%) |
| Metastasis condition | |
| Synchronous metastasis | 30 (85.7%) |
| Metachronous metastasis | 5 (14.3%) |
| Extrahepatic metastasisa | |
| Yes (%) | 13 (37.1%) |
| Lung (% of total metastasis) | 5 (14.3%) |
| Para-aortic lymph node (% of total metastasis) | 6 (17.1%) |
| Peritoneum (% of total metastasis) | 3 (8.6%) |
aOne patient had liver, lung, and peritoneal metastases at the same time. Thus, the sum of lung, para-aortic lymph node, and peritoneum number is fourteen